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Abstract 
Gestational diabetes mellitus (GDM) and preeclampsia (PE) are complications of pregnancy 
associated with adverse pregnancy outcomes and longer term health issues for mother and infant. 
The underlying pathogenesis of both is related to alterations in pregnancy metabolism. One aspect 
of metabolism that is considerably perturbed in both of these pathological states is maternal lipids. 
Chapter 1 presents reviews of the literature examining the role of maternal lipids in each of these 
conditions. 
The aims of this thesis were to: 
 To examine the effect of metformin as compared to insulin therapy on lipids in women with 
gestational diabetes 
 To examine the determinants of maternal triglycerides levels in women with gestational 
diabetes 
 To examine the relationship between maternal lipids and preeclampsia in women with 
gestational diabetes 
 To validate a triglyceride meter for use in measuring maternal capillary triglycerides in late 
pregnancy 
 To compare the expression of adipose triglyceride lipase, hormone sensitive lipase, 
lipoprotein lipase and endothelial lipase in placenta in uncomplicated pregnancies and 
pregnancies complicated by gestational diabetes and preeclampsia. 
Management of women with diabetes in pregnancy primarily focuses on maternal glucose and 
weight management. However, investigations in the non-pregnant setting have shown that the 
dietary management and pharmacotherapies we use have the potential to also alter maternal lipids. 
The metformin in gestational diabetes trial (MiG) allowed the examination of maternal lipids in the 
setting of a randomised controlled trial of women with GDM allocated to either metformin or 
insulin at the time when they needed to commence pharmacotherapy. This study (publication 1, 
Chapter 2) showed that maternal triglycerides were higher in women allocated to metformin 
compared with those allocated insulin, and that the strongest associations of infants being born large 
for gestational age (birth centile >90
th
) were maternal triglycerides and measures of glucose control 
at 36 weeks. The question then arises regarding what determines the higher triglyceride level found 
in women allocated metformin. This is explored in the second publication in Chapter 2 which 
demonstrated that at 36 weeks, maternal triglycerides were associated with glucose control in 
women allocated insulin and ethnicity in women allocated metformin. An examination of the 
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predictors of preeclampsia in women in the MiG study showed that at the time of commencement of 
pharmacotherapy for women with GDM, those more likely to develop preeclampsia later on have 
worse glucose control, greater early pregnancy weight gain, higher triglycerides and lower high 
density lipoprotein cholesterol (publication 2, Chapter 2). The last manuscript in Chapter 2 
examined the associations of preeclampsia in women in the MiG study. This found that a personal 
or family history of preeclampsia, maternal ethnicity, measures of glucose control, and triglycerides 
were significant predictors.  
Future exploration of the role of maternal triglycerides in pregnancy complications will require 
better characterisation of the daily flux in maternal triglycerides. Chapter 3 presents the validation 
of a triglyceride meter for use in pregnancy. A triglyceride meter would enable detailed study of the 
variability in maternal triglyceride levels, the effect of dietary or medication changes on maternal 
triglycerides, in much the same manner that capillary glucose levels have allowed examination of 
maternal glucose.  
Maternal lipoproteins do not diffuse across the placenta but must be disassembled into their 
components. Lipases are crucial to this process in other tissues and some have been previously 
shown to be expressed in placenta. Given the potential role of maternal triglycerides in infant 
outcomes in women with GDM and preeclampsia, the question arose of whether these triglycerides 
are passed to the infant and if so, whether that passage differs from normal in the setting of 
pregnancy pathology. To answer this question, placental lipases were examined. This data is 
presented in Chapter 4. For the first time, adipose triglyceride lipase (ATGL) has been confirmed to 
be present in human placenta and localised to the syncytiotrophoblast and decidual cells. Likewise, 
hormone sensitive lipase (HSL), endothelial lipase (EL) and lipoprotein lipase (LPL), were 
similarly present and localised. These studies showed some differences in mRNA expression for 
these lipases in placentae from women with GDM and normoglycaemic women and women with 
PE and normotensive women but no differences in protein expression or lipase activity (manuscript 
1 and 2, Chapter 4). These results show that the placenta has the apparatus for triglyceride transfer 
but suggest that it is not affected by the maternal pathologies of GDM or PE. The clinical 
differences seen in infants born to women with GDM or PE are therefore unlikely due to the action 
of these lipases. They may be due to either the difference in maternal lipids themselves or to other 
placental processes not examined here.  
In conclusion, maternal lipids are predictors of adverse maternal and neonatal outcomes in women 
with GDM. While maternal lipids differ between normal pregnancy and pregnancy complicated by 
GDM and PE and these lipids are associated with adverse infant outcomes, these studies found no 
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difference in four placental lipases suggesting the differences in infant outcomes may be directly 
due to maternal lipids or to other maternal or infant factors. Maternal triglycerides differ with the 
pharmacotherapy we utilise and future studies need to assess whether deliberately treating maternal 
lipids will improve pregnancy outcomes.  
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523. Reprinted with permission.  
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Introduction and context of the studies 
More than twenty years ago, a meeting of diabetes and pregnancy experts declared that one of the 
primary targets of research and management be the normalisation of pregnancy outcomes in women 
with diabetes mellitus (St Vincent Declaration in 1989: Diabet Med 1990;7:360). While outcomes 
have improved, they still lag behind women with uncomplicated pregnancies, particularly with 
regard to fetal growth and size, frequency of preeclampsia. 
Gestational diabetes mellitus (GDM) and preeclampsia (PE) are complications of pregnancy 
associated with marked alterations in pregnancy metabolism and both are linked to short and long 
term complications for mother and infant. The maternal longer term complications include the onset 
of maternal diabetes mellitus, hypertension, cardiac and renal disease in the years postpartum and 
similarly, for the infant, a higher risk of diabetes mellitus, obesity, hypertension and renal disease. 
Examination of the management of underlying associations of ill health for mother and infant have 
primarily focused on glucose (for gestational diabetes mellitus) and supportive therapies (for 
preeclampsia) and these have been our primary treatment targets to date. Despite this focus, 
morbidity for mother and infant continues to be associated with these conditions and we need to 
find more comprehensive management strategies.  
One aspect of metabolism that is considerably perturbed in both of these pathological states is 
maternal lipids. The aims of this thesis were to explore the role of maternal lipids in adverse 
pregnancy outcomes associated with maternal diabetes and preeclampsia. There are four chapters, 
which include eight stand alone manuscripts, of which 7 have been published and 1 are under 
review. Each manuscript consists of a literature review, methods, results and discussion. Citations 
for each manuscript – published, in proof and under review – appear within those papers.  
Chapter 1 presents two reviews of the literature: the first examining the role of maternal lipids in 
diabetes in pregnancy and the second examining the role of maternal lipids in preeclampsia. In 
Chapters 2, 3 and 4, each manuscript includes a literature review, methods, results and discussion. 
Additionally each of these chapters includes a brief introduction placing the studies in context for 
this thesis. Finally, the main findings of this thesis are summarised, and suggested directions for 
future research discussed.  
Specifically, Chapter 1 presents reviews of the literature for the role of maternal lipids in each of 
these conditions. The first manuscript has been published in Diabetes Care as a review paper and is 
presented in its published format. This manuscript discusses the abnormalities in maternal and 
placental lipid metabolism seen in maternal diabetes, and whether these are related to adverse 
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pregnancy outcomes. It goes on to explore the potential therapeutic options we would have to hand 
if we chose to treat maternal lipids directly and what is known about their safety in pregnancy. 
Lastly it discusses what needs to be done to fill in the gaps in our knowledge about this area.  
The second review manuscript has been published in  Hypertension in Pregnancy. This manuscript 
addresses the potential role of maternal lipids in the pathophysiology of preeclampsia.  
Chapter 2 includes three manuscripts. The first two have been published in Diabetes Care and are 
presented in their published form. The last is published in Journal of Diabetes and Metabolism and 
is presented in its published form. The first manuscript examines the influence of pharmacotherapy 
with either metformin or insulin on maternal and cord blood metabolic factors in women with 
GDM. The second examines the determinants of maternal triglyceride levels and the third examines 
the associations of maternal metabolic factors with preeclampsia. These manuscripts examine data 
from the Metformin in Gestational Diabetes trial, a randomised control trial of metformin or insulin 
for the pharmacological treatment of gestational diabetes. 
Chapter 3 includes a paper published in BMC Research Notes and is presented in its published 
form. This paper presents the findings of a validation study of a triglyceride meter for use in 
pregnancy. 
Chapter 4 includes two manuscripts. The first is published in PLOS One and is presented in its 
published form. The second is under review and is presented in its submitted form. These two 
manuscripts report on examinations of placental lipases in the settings of gestational diabetes 
mellitus and preeclampsia. 
Lastly, the Conclusions and potential Future Directions of the work comprising this thesis are 
discussed 
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Context of the studies in Chapter 1 
The two review papers following examine the role of maternal lipids in the adverse pregnancy 
outcomes associated with diabetes in pregnancy and preeclampsia.  
The first manuscript has been published in Diabetes Care as a review paper. It is reproduced with 
permission.  This manuscript discusses the abnormalities in maternal and placental lipid metabolism 
seen in maternal diabetes, and whether these are related to adverse pregnancy outcomes. It goes on 
to explore the potential therapeutic options we would have to hand if we chose to treat maternal 
lipids directly and what is known about their safety in pregnancy. Lastly it discusses what needs to 
be done to fill in the holes in our knowledge about this area.  
The second manuscript has been published in Hypertension in Pregnancy. This manuscript 
considers the role of maternal lipids in the pathophysiology of and maternal and offspring outcomes 
following preeclampsia. It then considers evidence around abnormal lipid genes and their role in 
preeclampsia and lastly treatment of hyperlipidaemia in preeclampsia.  
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Research questions and aims in this thesis 
The general purpose of the studies in this thesis was to examine the importance of lipids in the 
pregnancy complications of gestational diabetes and preeclampsia. Firstly, the role of maternal 
lipids in the clinical outcomes of gestational diabetes and preeclampsia. Secondly, whether in 
addition to elevated maternal triglycerides, there is abnormal placental triglyceride processing in 
these settings.  
Research questions and aims, chapter 2: 
Questions: 
 How do maternal lipids vary with the pharmacological therapies we use to treat gestational 
diabetes? 
 Given that maternal triglycerides in late pregnancy differ with pharmacological therapy, 
what determines maternal triglyceride levels? 
 Are maternal lipids at the time of commencement of pharmacotherapy for gestational 
diabetes related to the risk of preeclampsia?  
Aims: 
 To examine the effect of metformin as compared to insulin therapy on lipids in women with 
gestational diabetes 
 To examine the determinants of maternal triglycerides levels in women with gestational 
diabetes 
 To examine the relationship between maternal lipids and preeclampsia in women with 
gestational diabetes 
  
Research question and aim, chapter 3: 
Question: 
 Can a triglyceride meter be used to reliably measure maternal capillary triglycerides in late 
pregnancy?  
Aim: 
 To validate a triglyceride meter for use in measuring maternal capillary triglycerides in late 
pregnancy 
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Research question and aim, chapter 4: 
Question: 
 Does placental triglyceride processing differ between women with normal and abnormal 
pregnancy, specifically gestational diabetes and preeclampsia? 
Aim: 
 Examine adipose triglyceride lipase, hormone sensitive lipase, lipoprotein lipase and 
endothelial lipase expression and overall lipase activity in placentae from uncomplicated 
pregnancies as compared to placentae from pregnancies complicated by gestational diabetes 
or preeclampsia. 
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Barrett HL, Dekker Nitert M, Jones L, O’Rourke P, Lust K, 
Gatford, KL,  De Blasio MJ, Coat S, Owens JA, Hague 
WM, McIntyre HD, Callaway LK, Rowan J Diabetes Care 
(2013) 36, 1941-1946. 
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Context of the studies in Chapter 2 
The three manuscripts included in this chapter explore the role of maternal lipids in pregnancy 
complications in gestational diabetes mellitus. The first two have been published in Diabetes Care. 
They are reproduced with permission. The third is published in Journal of Diabetes and 
Metabolism. 
The data for these three manuscripts was obtained with thanks from Dr Janet Rowan (Auckland) 
and the investigators of the Metformin in Gestational Diabetes (MiG) trial. The MiG trial was a 
multisite, multiethnic, randomised controlled trial of instituting metformin as compared to insulin 
therapy (in combination with standard dietary and lifestyle advice) in women with gestational 
diabetes needing pharmacotherapy to control their glucose levels.  
As discussed in the review manuscript, the current therapies we use for treatment of diabetes in 
pregnancy have the ability to influence maternal lipids (and indeed metabolism generally) in 
different ways. Prior to beginning to deliberately target maternal lipids in pregnancy, we need to 
know more about how they are influenced by our current therapies. The MiG trial dataset provides a 
unique opportunity to examine this in an extremely well clinically and metabolically characterised 
cohort, randomised to the two most common pharmacotherapies we use to manage diabetes in 
pregnancy.  
The purpose of the first of the manuscripts in this chapter was therefore to examine the influence of 
metformin as compared with insulin therapy on maternal lipids in the setting of gestational diabetes 
and their relationship to pregnancy outcomes.  
Given the difference seen in maternal triglycerides between women allocated metformin as 
compared to insulin in the first paper in the current chapter, the purpose of the second manuscript 
was to explore the determinants of maternal triglycerides and try to understand what underlies the 
differences reported in the first manuscript.   
Lastly, given that maternal triglycerides have been implicated in preeclampsia, as discussed in the 
second review paper, I asked the question of whether, in this well characterised group of women, 
maternal lipids were predictors of the development of preeclampsia. This analysis examines the 
associations of maternal preeclampsia at the point of enrolment in to the MiG trial, prior to 
pharmacotherapy starting, with a diagnosis of preeclampsia.  
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metabolic and cardiovascular risk in the Metformin 
in Gestational diabetes (MiG) trial: responses to 
maternal metformin vs. insulin treatment. 
Barrett HL, Gatford, KL, Houda CM, De Blasio MJ,McIntyre HD, Callaway LK, 
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Copyright 2013 American Diabetes Association 
From Diabetes Care
®
, Vol. 36, 2013; 529-536 
Reprinted with permission from The American Diabetes Association. 
 
 
 
55 
 
56 
 
 
57 
 
  
 Table C-1 Maternal outcomes 
58 
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 Figure C-1 Correlations between maternal variables and between cord plasma variables and birth weight. 
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Figure D-1 Percent change in maternal triglycerides and HbA1c, by ethnicity 
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 Table D-3 Supplementary Table 1: Maternal characteristics at enrolment and 36 weeks. 
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 Table D-4 Supplementary Table 2: Measures of maternal glucose and triglycerides, by treatment. 
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 Table D-5 Supplementary Table 3: Variables associated with maternal triglycerides, univariate. 
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 Table D-6 Supplementary Table 4: Variables associated with maternal triglycerides, univariate, by treatment. 
77 
 
  
 Table D-7: Supplementary table 5: Associations with maternal triglycerides, multivariate, by treatment. 
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 Table E-1: Comparison of demographic and pregnancy variables at enrolment between normotensive women and those 
with preeclampsia 
  
82 
 
 Table E-2: Logistic regression for the outcome of preeclampsia diagnosis using variables at enrolment in the study.  
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GH women  
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Discussion and implications of findings, Chapter 2 
The purpose of the first of the manuscripts in this chapter was to examine the influence of 
metformin as compared with insulin therapy for the treatment of gestational diabetes. This study 
showed that women randomised to metformin had a greater increase in maternal triglycerides from 
~ 30 weeks gestation to 36 weeks gestation, while gaining less weight and having similar glycaemic 
control. Further, the predictors of infants being born large (>90
th
 centile) were maternal 
triglycerides and measures of glucose control.  
One subtle but interesting finding was that the relationship between maternal HDL cholesterol at 36 
weeks and infant birth weight differed between treatment arms. Maternal HDL cholesterol was 
negatively correlated with birthweight in women on insulin and not related in women on metformin. 
This was without any difference in maternal or cord blood HDL levels between treatment arms. 
This raises questions about what may underlie this, as expanded upon in the discussion of the first 
manuscript in this chapter and raises questions to be answered in future studies.  
Given the difference in maternal triglycerides between women allocated metformin as compared to 
insulin, the purpose of the second manuscript was to explore the determinants of maternal 
triglycerides.  This study found that the determinants of maternal triglycerides differed with the 
allocated pharmacological therapy. Overall, for women allocated to insulin, glucose control was 
important and for women allocated to metformin, ethnicity had the strongest relationship. 
Lastly, given that maternal triglycerides have been implicated in preeclampsia, I asked the question 
of whether, in this well characterised group of women, maternal lipids were implicated in the 
development of preeclampsia. This analysis examines the associations of maternal preeclampsia at 
the point of enrolment in to the MiG trial, prior to pharmacotherapy starting. This study found that a 
personal or family history of preeclampsia, Polynesian ethnicity, degree of hyperglycemia, maternal 
triglycerides and weight gain prior to treatment signalled increased risk of subsequent preeclampsia 
in women needing pharmacotherapy for GDM. 
This series of analyses tells us that the pharmacotherapy option we choose for women with 
gestational diabetes influences maternal triglycerides, and further, maternal triglycerides are 
associated with the risk of infants being born large and also associated with preeclampsia.  
As discussed in the reviews in Chapter 1, one weakness of this and other studies examining 
maternal lipids in pregnancy is that they are frequently based on fasting lipids. We know with 
maternal glucose levels, that postprandial levels are important and associated with pregnancy 
outcomes. In the studies described here in Chapter 2, maternal triglycerides have been shown to be 
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important in pregnancy outcomes.  It would be useful therefore to have the ability to examine the 
fluctuations in maternal triglycerides through the day, in the woman’s home setting and under the 
influence of her usual eating habits and activity levels. This is the purpose of the study in Chapter 3. 
Given the association of maternal triglycerides with infant growth, and the elevated maternal 
triglycerides in women with preeclampsia described in the current chapter, an obvious question to 
ask is whether it is just the maternal milieu that differs or whether there is a change in placental 
lipid processing as well. Chapter 4 examines lipases in the placenta in the settings of gestational 
diabetes and preeclampsia. 
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Chapter 3  
Investigation of a method 
to monitor triglyceride 
levels at home. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Validation of a triglyceride 
meter for use in pregnancy 
Barrett HL, Dekker Nitert M. D’Emden M, 
McIntyre HD, Callaway LK., 
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September 2014) 
Reprinted with permission 
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Context of the study in Chapter 3 
As described in the reviews in Chapter 1 and found in the analyses of the MiG data in Chapter 2, 
maternal triglycerides are associated with the common complications of diabetic pregnancy 
including infants being large for gestational age and preeclampsia. As discussed in the review 
papers in Chapter 1, one flaw in the current literature is that at best, maternal triglycerides have 
been measured at a few isolated points in time during pregnancy, or in the setting of a formal meal 
test and are frequently done fasting. In contrast, maternal home glucose monitoring is central to the 
management of diabetes in pregnancy and maternal postprandial glucose levels have been shown to 
relate to pregnancy outcomes. We currently entirely lack information on routine daily fluctuations 
in maternal triglycerides in the setting of pregnancy and under “free-range” conditions. In order to 
be able to understand the role of maternal triglycerides in pregnancy outcomes, or to analyse how 
potential lifestyle or pharmacological therapies are impacting maternal triglycerides, we need to 
know what they are like and how they flux over time. The purpose of the study in this chapter was 
to examine the validity of a triglyceride meter for use in pregnancy.  
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F. Validation of a triglyceride meter for use in 
pregnancy  
Barrett HL, Dekker Nitert M, D’Emden M, McIntyre HD, Callaway LK 
BMC Research Notes 2014, 7:679 (29 September 2014) 
Reprinted with permission
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 Figure F-1: Graphs of comparison between methods 
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Discussion and implications of findings, Chapter 3 
This study demonstrates that the triglyceride meter examined accurately measures triglycerides in 
women in the late third trimester of pregnancy. While further studies need to be undertaken 
examining the ease of use and reliability of the meter in the hands of a patient, it does offer a 
potential tool for clinical use.  
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complicated 
pregnancy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Placental lipases in pregnancies 
complicated by gestational diabetes 
mellitus (GDM) 
Barrett HL, Kubala M, Scholz Romero K, McIntyre HD, 
Denny K, Woodruff T, Callaway LK, Dekker Nitert M.  
PLoS ONE 9(8): e104826. 
doi:10.1371/journal.pone.0104826 
Reprinted with permission 
 
 
Placental lipases in pregnancies 
complicated by preeclampsia.  
Barrett HL, Kubala M, Scholz Romero K, McIntyre HD, 
Denny K, Woodruff T, Callaway LK, Dekker Nitert M.  
Under Review
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Context of the studies in Chapter 4 
 
As discussed in the review manuscripts in Chapter 1, maternal lipids are abnormal in the setting of 
diabetes and preeclampsia and placental function is also altered. Given the changes in maternal 
triglycerides with pharmacotherapy and the relations between maternal triglycerides and pregnancy 
outcomes outlined in Chapter 2, the next question is whether placental function is also altered and 
whether these changes underlie the relationships seen between maternal triglycerides and pregnancy 
outcomes. The two studies included in this chapter examine lipases in the placenta. Specifically 
adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), lipoprotein lipase (LPL) and 
endothelial lipase (EL). Lipases are central to the metabolism and storage of triglycerides, with 
ATGL and HSL being intracellular and involved in lipolysis in the lipid droplet.  
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G. Placental lipases in pregnancies complicated by 
Gestational Diabetes Mellitus (GDM). 
 
Barrett HL, Kubala M, Scholz Romero K, McIntyre HD, Denny K, 
Woodruff T, Callaway LK, Dekker Nitert M. 
PLoS ONE 9(8): e104826. doi:10.1371/journal.pone.0104826 
Reprinted with permission 
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 Table G-1: Maternal and pregnancy characteristics 
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 Figure G-1:ATGL, GDM vs control placentae 
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Figure G-2: HSL, GDM vs control placentae 
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 Figure G-3: LPL, GDM vs control placentae 
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 Figure G-4:EL, GDM vs control placentae 
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 Table G-2: Supplementary Table 1 Primer sequences 
Gene 
name 
Forward primer Reverse primer 
LPL 5’-TGGATCGCTCCACTTTGACC 5’-GGGCTTCGGACTGGTAAACA 
LPIG 5’-GTCCAGCCCCTGCTATCTCA 5’-CCTTTTCAAACTGACCCTTGCC 
LIPE 5’-CACATTAGACCCAGAAGATGCC 5’-GGCAGCGAAACTTGACAGTG 
PNPLA2 5’-TGCCCACTTTGTGTGTATGTG 5’-CCAGGAGTGCGACGCT 
PLIN1 5’-GAAGTTGAAGCTTGAGGAGCG 5’-GGCTTCCTTAGTGCTTGGTGT 
ABHD5 5’-GAACGACCAGACCTTGCTGA 5’-GCTGTCTCACCACTTGGAGT 
G0S2 5’-CACTAAGGTCATTCCCGCCT 5’-AGCACGTACAGCTTCACCAT 
CK7 5’- CCGTGCGCTCTGCCTATGGGG 5’- GCTCCAGAAACCGCACCTTGTCGAT 
CD34 5’- CCACAGGAGAAAGGCTGGGCGA 5’- AGCCCCTCGGTTCACACTGGC 
DES 5’- TCCGAGAAACCAGCCCTGAGCAA 5’- GTGGCCTCACTGACGACCTCCC 
ACTB 5’-AGCGAGCATCCCCAAAGTT 5’-GGGCACGAAGGCTCATCATT 
 
 
 
 
 
 
 
 
